(NASDAQ:GRPN), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Groupon, Inc. (“Groupon” or the “Company”) (NASDAQ: GRPN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Groupon and certain of its officers and/or directors have engaged […]
(NasdaqGM:ALT), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged
(NASDAQ:UNCY), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Unicycive and certain of its officers and/or directors have
(NYSE:DOW), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Dow Inc. (“Dow” or the “Company”) (NYSE: DOW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Dow and certain of its officers and/or directors have engaged
(NASDAQ:LINE), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Lineage, Inc. (“Lineage” or the “Company”) (NASDAQ: LINE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Lineage and certain of its officers and/or directors have engaged
(NYSE:SOC), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Sable Offshore Corp. (“Sable” or the “Company”) (NYSE: SOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sable and certain of its officers and/or directors have
(NYSE:KBR), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether KBR and certain of its officers and/or directors have engaged
(NYSE:UNFI), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of United Natural Foods, Inc. (“United Natural” or the “Company”) (NYSE: UNFI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether United Natural and certain of its officers
(NYSE:SJM), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of The J.M. Smucker Company (“Smucker” or the “Company”) (NYSE: SJM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Smucker and certain of its officers and/or directors
(NYSE:EHC), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation (“Encompass” or the “Company”) (NYSE: EHC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Encompass and certain of its officers and/or directors have